戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed to obtain sufficient numbers of cells for cellular immunotherapy.
2  detection of T cell populations relevant to cellular immunotherapy.
3 a novel approach for vaccine development and cellular immunotherapy.
4 in NPC renders it an appealing candidate for cellular immunotherapy.
5 d underscores their potential application in cellular immunotherapy.
6 h in animal models and in clinical trials of cellular immunotherapy.
7 xpansion of these cells for potential use in cellular immunotherapy.
8 imerism as a potential platform for adoptive cellular immunotherapy.
9  in the development of new forms of adoptive cellular immunotherapy.
10 ymopoiesis, and the use of adjuvant-targeted cellular immunotherapies.
11 ress, which influences delivery of drugs and cellular immunotherapies.
12                                     Adoptive cellular immunotherapy (ACT) is a potentially curative t
13 cancer vaccine trials, but also for adoptive cellular immunotherapy after ex vivo expansion.
14 ces in laboratory and clinical procedures in cellular immunotherapy, along with the development of po
15 e this metabolic quiescence and thus augment cellular immunotherapy-based cancer therapy.
16 lantation and after transplantation adoptive cellular immunotherapy but may be complicated by a high
17                                         This cellular immunotherapy can modulate beta chemokine produ
18  understanding of ongoing cancer vaccine and cellular immunotherapy clinical trials.
19                           Tumor vaccines and cellular immunotherapies could synergize with checkpoint
20 trategies in cytokine therapy, vaccines, and cellular immunotherapy, each of which might become viabl
21                           Tumor vaccines and cellular immunotherapies enhanced OS and PFS in NSCLC.
22 isease onset, suggesting a novel approach to cellular immunotherapy for autoimmunity.
23 uggest a potential novel approach to augment cellular immunotherapy for cancer.
24 HSCT) has evolved into an effective adoptive cellular immunotherapy for the treatment of a number of
25 be critical in developing effective adoptive cellular immunotherapy for viral infections and cancer.
26 nce EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment op
27           Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy i
28 onments, to generate more effective adoptive cellular immunotherapies in cancer, and to direct T cell
29  a strong rationale for the investigation of cellular immunotherapy in B-cell NHL.
30  produce tumor-specific T cells for adoptive cellular immunotherapy in melanoma patients.
31 sessed the efficacy of tumor vaccination and cellular immunotherapy in NSCLC.
32 mediated cytotoxicity in vitro, and adoptive cellular immunotherapy in vivo.
33                                         This cellular immunotherapy is a short-term available and bro
34                                   Allogeneic cellular immunotherapy is effective even with the use of
35                                   Autologous cellular immunotherapy is hindered by the inability to b
36 ssing the potential of CD4+ CD25+ Tregs as a cellular immunotherapy is their hypoproliferative phenot
37                                              Cellular immunotherapy may provide a strategy to overcom
38 bes future avenues for their exploitation in cellular immunotherapy of malignant blood disorders.
39 mized controlled trials (RCTs) investigating cellular immunotherapy or vaccines in NSCLC.
40                                 This form of cellular immunotherapy presents a unique opportunity to
41 ipulation of OX40 may be useful in improving cellular immunotherapy regimes for treatment of persiste
42 l rationale to target them as a personalized cellular immunotherapy strategy, an especially appealing
43 ), this tumor is an attractive candidate for cellular immunotherapy targeted against tumor-associated
44 ests this tumor can be highly susceptible to cellular immunotherapy targeted to tumor associated anti
45 enrolled onto a clinical trial of autologous cellular immunotherapy targeting human epidermal growth
46                          We have developed a cellular immunotherapy that uses chimeric receptors to s
47            Despite the major improvements in cellular immunotherapy, the immunogenicity of virus-spec
48 ress in the application of novel humoral and cellular immunotherapies to children and adolescents wit
49 ts, these cells have potential to be used as cellular immunotherapy to control transplant arterioscle
50                                              Cellular immunotherapy to prevent CMV disease is less to
51 uld potentially serve as target antigens for cellular immunotherapy to promote GVL activity after all
52 y and gammadelta T cell-based drug resistant cellular immunotherapy to treat GBM.
53                                     Adoptive cellular immunotherapy treats metastatic cancer by infus
54 were performed in anticipation of its use in cellular immunotherapy trials for primary malignant brai
55  novel nontoxic and efficacious paradigm for cellular immunotherapy trials in human primary malignant
56 mmunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transpla
57                                     Adoptive cellular immunotherapy utilizing tumor-reactive T cells
58                                              Cellular immunotherapy was found to be more effective th
59 d mixed chimerism as a platform for adoptive cellular immunotherapy was reliably induced.
60 Lapuleucel-T (APC8024), an autologous active cellular immunotherapy, was prepared from peripheral-blo
61                            Autologous active cellular immunotherapy with lapuleucel-T was feasible, s
62  allogeneic T cells thus represent a form of cellular immunotherapy with time-limited biologic activi

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。